We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A judge granted a motion to stop a subpoena compelling a deposition of a New England Journal of Medicine (NEJM) editor in Merck’s Vioxx litigation, saying the drug company’s actions were “abusive and arrogant.”
The Supreme Court’s recent ruling upholding the right of a patent licensee to sue the patent holder may ease market entry for generic drug manufacturers who rely on abbreviated new drug applications to challenge the enforceability and validity of brand drug patents.
The Supreme Court’s recent ruling upholding the right of a patent licensee to sue the patent holder may ease market entry for generic drug manufacturers who rely on abbreviated new drug applications to challenge the enforceability and validity of brand drug patents.
A company’s right to challenge a patent that it is licensed to use is not restricted by the licensing agreement between it and the patent holder, the U.S. Supreme Court said in a Jan. 9 ruling.
Armed with several production and method-of-use patents to cover its cancer drug Thalomid, Celgene said it is preparing a legal challenge to head off Barr Laboratories’ move to market thalidomide, a generic version of the drug, company executives said.
The production, sale and distribution of Pravachol and generic pravastatin sodium by Bristol-Myers Squibb (BMS) and Watson
Pharmaceuticals are being challenged in federal court.
Plaintiffs are asking the Supreme Court to review the dismissal of a case to determine the legality of reverse payment agreements, where brand drugmakers pay generic rivals to keep their low-cost versions of prescription products off the market.
A federal court has upheld a preliminary injunction preventing Watson subsidiary Andrx Pharmaceuticals from marketing clarithromycinn, a generic version of Abbott Laboratories’ extended-released antibiotic Biaxin XL.
A judge granted a motion to stop a subpoena compelling a deposition of a New England Journal of Medicine (NEJM) editor in Merck’s Vioxx litigation, saying the drug company’s actions were “abusive and arrogant.”
A Canadian court ruling that dismissed an appeal request by Apotex signals another defeat for the generic drugmaker in its efforts to market generic clopidogrel bisulfate.